| Description | This product is a anti-SARS-CoV-2 Spike S1 human antibody J08. It is able to bind and interfere with the RBD/ACE2 interaction with all tested variants. J08 shows an neutralizing ability against most SARS-CoV-2 variants of concern (VoCs) including D614G, Alpha, Beta, Gamma, and Delta variants. J08 has low nanomolar affinity and binds high on the receptor binding domain (RBD) ridge independent of known escape mutations. J08 can be used in cell-based assays. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 (D614G, Alpha, Beta, Gamma and Delta) |
| Epitope | J08 can bind dynamic RBD conformations. |
| Affinity | 98 nM |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | The ELISA was done by using antibody started at 10 μg/mL with a serial 1:4 dilution. The results of Neutralization assay showed that J08 is able to potently neutralize most variants of concern (VoCs). |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
